Road sign displaying the words Fast Track against a blue sky

RESEARCH

16 Jan 2026

FDA Fast Tracks Dual-Action MASH Drug: Is Momentum Back?

FDA grants two expedited reviews to a dual-action MASH drug, reviving interest in metabolic approaches without signaling a policy overhaul

Lilly and Nimbus Therapeutics logos displayed to mark an obesity drug development partnership

PARTNERSHIPS

13 Jan 2026

Big Pharma’s Next Obesity Bet Comes in Pill Form

Drugmakers push oral obesity pills into late trials, aiming to move weight loss care beyond injections and into mass-market medicine

Eli Lilly corporate headquarters sign outside company office building

INVESTMENT

12 Jan 2026

Lilly’s Ventyx Deal Points to a Future Beyond Injections

Eli Lilly’s $1.2B Ventyx buy shows growing confidence in oral small-molecule drugs aimed at inflammation and long-term metabolic health

Oral weight loss pills with measuring tape illustrating shift in obesity treatment

MARKET TRENDS

8 Jan 2026

Oral Weight Loss Pills Are Shaking Up Metabolic Care

Oral obesity drugs are widening access, shifting pricing power, and forcing drugmakers and health platforms to rethink how metabolic care ...

Pfizer research facility following Metsera acquisition in obesity drug strategy

PARTNERSHIPS

6 Jan 2026

Pfizer’s Metsera Deal Ignites a New Obesity Drug Arms Race

Pfizer’s Metsera buy sharpens its obesity strategy and signals a fiercer, faster fight for metabolic drug leadership

Ionis Pharmaceuticals sign representing liver-targeted drug research for MASH

RESEARCH

19 Dec 2025

Liver-First Drugs Redefine the Next Phase of the MASH Race

New 2025 data for Ionis ION224 highlight how liver-targeted drugs and GLP-1s may converge to reshape MASH care and deal-making

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.